BOULDER, Colo., Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 in both an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting, taking place September 3-6, 2025, at the George R. Brown Convention Center in Houston, Texas. This is an encore presentation of data that were previously presented at the European Hematology Association (EHA) 2025 Congress.

Details of the presentation are as follows:

Title: ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::

See Full Page